Business Context and Reporting Period
This Form 6-K filing by GSK plc covers the month of December 2023, with a specific reporting date of December 13, 2023. The document serves as a transaction notification regarding the acquisition of Ordinary Shares by Persons Discharging Managerial Responsibilities (PDMRs) under the Company's Share Reward Plan.
Key Financial Metrics
The filing does not provide consolidated financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. It exclusively details specific share transactions executed on December 11, 2023, on the London Stock Exchange (XLON).
| Instrument | Transaction Type | Price per Share | Total Volume |
|---|---|---|---|
| Ordinary Shares (31 1/2 pence each) | Acquisition under Share Reward Plan | £14.4015 | 146 Shares (Aggregated) |
Note: The aggregated volume represents the sum of partnership and matching shares acquired by eight executives.
Material Changes
This filing does not report material changes to the company's financial position, operations, or strategy compared to prior periods. It is a routine disclosure of executive share acquisitions.
Guidance, Outlook, and Risks
The filing contains no management commentary, forward-looking guidance, risk factors, or contingencies. It is a statutory notification of insider trading activity compliant with regulatory requirements.
Key Facts for Investor Verification
- Transaction Date: All reported transactions occurred on December 11, 2023.
- Participants: Eight PDMRs participated, including CEO Emma Walmsley, CFO Julie Brown, and Company Secretary Victoria Whyte.
- Transaction Nature: All acquisitions were made under the Company's Share Reward Plan, consisting of partnership shares and matching shares.
- Share Price: The uniform price for all transactions was £14.4015 per share.
- Volume Discrepancy: Most executives acquired 18 shares (9 partnership + 9 matching), while Sally Jackson and Victoria Whyte acquired 16 shares (8 partnership + 8 matching).